当前位置：
X-MOL 学术
›
Ann. Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma
Annals of Oncology ( IF 56.7 ) Pub Date : 2017-06-14 , DOI: 10.1093/annonc/mdx289 M. Dreyling , F. Morschhauser , K. Bouabdallah , D. Bron , D. Cunningham , S.E. Assouline , G. Verhoef , K. Linton , C. Thieblemont , U. Vitolo , F. Hiemeyer , M. Giurescu , J. Garcia-Vargas , I. Gorbatchevsky , L. Liu , K. Koechert , C. Peña , M. Neves , B.H. Childs , P.L. Zinzani
Annals of Oncology ( IF 56.7 ) Pub Date : 2017-06-14 , DOI: 10.1093/annonc/mdx289 M. Dreyling , F. Morschhauser , K. Bouabdallah , D. Bron , D. Cunningham , S.E. Assouline , G. Verhoef , K. Linton , C. Thieblemont , U. Vitolo , F. Hiemeyer , M. Giurescu , J. Garcia-Vargas , I. Gorbatchevsky , L. Liu , K. Koechert , C. Peña , M. Neves , B.H. Childs , P.L. Zinzani
Copanlisib is a pan-class I phosphatidylinositol 3-kinase inhibitor with predominant activity against the α- and δ-isoforms.
中文翻译：
PI3K抑制剂copanlisib在复发或难治性，惰性或侵袭性淋巴瘤的II期研究
Copanlisib是一种泛I类磷脂酰肌醇3-激酶抑制剂，对α-和δ-同种型具有主要活性。
更新日期：2017-09-18
中文翻译：
PI3K抑制剂copanlisib在复发或难治性，惰性或侵袭性淋巴瘤的II期研究
Copanlisib是一种泛I类磷脂酰肌醇3-激酶抑制剂，对α-和δ-同种型具有主要活性。
京公网安备 11010802027423号